ReSTORing good vision

Article

The diffractive AcrySof ReSTOR (Alcon) intraocular lens (IOL) can provide stable, high levels of spectacle independence for both near and distance vision.

The diffractive AcrySof ReSTOR (Alcon) intraocular lens (IOL) can provide stable, high levels of spectacle independence for both near and distance vision, according to Rudy Nuijts and colleagues from the Academic Hospital Maastricht, The Netherlands.

A total of 45 eyes of 23 patients who received the ReSTOR SA60D3 IOL were followed in a prospective trial. Patients were assessed preoperatively and six months and three years postoperatively.

No significant changes in uncorrected distance visual acuity (UCDVA) and best corrected distance visual acuity (BCDVA) were noted between the six month and three year time points.

At six months postoperatively, 78% and 83% of patients no longer required spectacles for near and distance vision respectively. At three years 73% and 74% of patients still did not require spectacles for near and distance vision, respectively. Near vision without glasses at six months and three years was 4.0 and 3.7, respectively and 4.3 and 3.8 for distance vision, respectively. Ninety percent of subjects declared themselves to be satisfied with intermediate vision tasks at both time points. Moderate to severe glare was reported by 9.9% and 4.3% at six months and three years and halos were reported by 8.7% and 4.3%, respectively.

Dr Nuijts and his colleagues concluded that the ReSTOR lens achieves excellent near and distance visual results in the majority of patients.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.